Eighth Patient Treated with Sealantis Novel Alga-Mimetic Sealant
Sealantis Conveys Nature’s Power to Prevent Dangerous Leakage of Bodily Fluids
HAIFA, Israel, June 27, 2013 /PRNewswire/ –
Sealantis [http://www.sealantis.co.il ] Ltd., a private start-up from the
Technion-Israel Institute of Technology, reports that an eighth patient was treated with
Seal-V, its alga-mimetic vascular sealant, as part of the company’s first clinical study.
Seal-V is a protein-free sealant, designed to resolve current limitations and challenges
in control of surgical bleeding. It is expected to receive CE Mark within the year.
The clinical trial, taking place in Israel, is evaluating the safety and efficacy of
achieving hemostasis in large peripheral blood vessels using the Seal-V protein-free
Sealantis is a 6-year-old startup, located on campus of one of Israel’s leading
academic centers – the Technion. It was founded by Prof. Havazelet Bianco-Peled, a world
renowned expert in biomedical polymers.
Since the early 2000s, Prof. Bianco-Peled had been researching the adhesion mechanism
of algae to rocks underwater. The research unveiled the chemical composition of the algae
adhesive, but it was the professor’s invention of a synthetic, alga-mimetic adhesive that
enabled harnessing nature’s power for practical and commercial uses.
In 2007, the invention was embraced by the Alfred Mann Institute at the Technion,
which is funding the company. While having potential uses in a variety of industrial
applications, Sealantis chose to focus on urgent medical needs – controlling leakage of
body fluids through surgical or traumatic wounds. Such leaks can be fatal since sutures or
staples are not fully leak-proof. “Sealing surgical incisions requires sticking to wet or
moist surfaces, which is a challenge that most known adhesives can’t usually meet,”
explains Prof. Bianco-Peled.
Surgical sealants represent a market of over $1.0 billion which grows 14% annually.
“When I look at the market, it’s clear to me that there is no single winning solution,”
says Dr. Zeev Gilkis, AMIT CEO and Sealantis Ltd. Chairman, “There are some good products,
but each one has drawbacks or is limited to a specific application. Sealantis brings a
versatile yet simple technology, addressing unmet clinical needs…”
“Seal-V is overcoming a clinical need with its unique features, which offer
simultaneous sealing and hemostasis for native and synthetic vascular fields,” explains
Prof. Vincent Riambau, Chief of Vascular Surgery Division, Hospital Clinic, University of
Barcelona, and Past President of the European Society of Vascular Surgery (ESVS), who
serves on the Clinical Advisory Board of Sealantis. “It is accomplishing valuable
qualities for vascular surgery, being quick, easy to use, effective and safe. It will
surely be most welcome to the vascular community.”
Sealantis Ltd. is currently planning its next regulatory steps toward a PMA study and
FDA approval of Seal-V and is working on strategic partnerships towards the coming market
About Sealantis Ltd.
Sealantis Ltd. is developing a proprietary platform of alga-mimetic tissue adhesives,
for a variety of applications and clinical needs in surgical leakage control, tissue
adhesion and drug delivery. The Sealantis adhesives are protein-free, and have an
extraordinary ability to adhere strongly to internal tissues even in wet environments.
Sealantis Ltd. was founded in 2007 by Prof. Havazelet Bianco-Peled, and is supported by
the Alfred Mann Institute at the Technion (AMIT). http://www.sealantis.co.il
The Alfred Mann Institute at the Technion – AMIT supports the development and
commercialization of biomedical innovations conceived by Technion researchers. Established
in 2006 by the Technion and Dr. Alfred E. Mann, an American entrepreneur and
philanthropist, the institute aspires to bridge the well-known gap between academic
research and commercial success. AMIT currently manages four ventures, including Sealantis
CONTACT Tehilla Bar Yehuda Business Development Sealantis Ltd. +972-50-3683339 Tehillab@gmail.com